维泰瑞隆宣布委任王舒展先生为董事会董事

Core Insights - Vitarion, a clinical-stage biotechnology company, focuses on developing transformative therapies for neurodegenerative diseases, inflammatory immune diseases, metabolic diseases, and rare diseases [1][3] - The company announced the appointment of Wang Shuzhan, Managing Director of Qiming Venture Partners, to its board, enhancing its leadership with his extensive experience in the life sciences sector [1][2] - Vitarion has a diverse pipeline of projects, including clinical studies on SARM1 inhibitor SIR2501, NAMPT agonist SIR4156, and RIPK1 inhibitor SIR9900, while also advancing preclinical research [3] Company Overview - Vitarion was established in 2017 and has built a robust scientific foundation with a focus on key pathogenic mechanisms related to aging, degenerative changes, metabolic dysfunction, and inflammation [3] - The company was recognized in the 2025 Endpoints 11 list of most promising biotechnology startups, indicating its potential in the industry [3]